Skip to main content

BioGeneration Ventures — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

47
Companies
$2.2B
Total invested
$58.5M
Avg. check
18
Industries
Biotechnology 18Health Care 13Medical 10Therapeutics 9Life Science 4Neuroscience 3+12 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 47
Tanai Therapeutics
September 2024

Therapeutics for obesity and obesity-related conditions.

Health Care · Gent$3.5M Seed
Brenig Therapeutics
July 2024

Brenig Therapeutics develops therapies for neurodegenerative disorders.

Health Care · Dover$65.0M Series A
CatalYm
July 2024

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

Biotechnology · Planegg$150.0M Series D
Dualyx
May 2023

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Biotechnology · Ghent$43.5M Series A
Phosphoenix
April 2025

Phosphoenix is a neurotechnology company.

Health Care · Delft$342K Debt Financing
Complement Therapeutics
April 2023

Complement Therapeutics operates as a preclinical stage company.

Biotechnology · London$78.7M Series A
FundaMental Pharma
April 2024

FundaMental Pharma is a neuroscience company with a portfolio at the preclinical stage.

Health Care · Heidelberg$2.9M Seed
Scenic Biotech
March 2022

Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.

Biometrics · Amsterdam$31.0M Series A
Azafaros
May 2025

Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.

Biotechnology · Leiden$146.7M Series B
Avidicure
April 2025

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.

Oegstgeest$50.0M Seed
VarmX
February 2025

VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.

Manufacturing · Leiden$15.8M Venture - Series Unknown
Citryll
December 2024

Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.

Biopharma · Oss$89.7M Series B
VectorY
November 2023

VectorY is an integrated gene therapy company focused on development of therapeutics for CNS, somatic disorders and muscle diseases.

Biotechnology · Amsterdam$138.0M Series A
Mironid
September 2023

Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer.

Biotechnology · Newhouse$38.3M Series A
Tiga TX
December 2024

Tiga TX develops an IgA therapeutic monoclonal antibody platform for the treatment of solid tumors.

Biotechnology · Boston$35.5M Grant
TargED Biopharmaceuticals
December 2025

TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.

Biopharma · Utrecht$25.3M Series A
River BioMedics
January 2022

River BioMedics is a biotech company that aims to develop human 3D in vitro 3D human heart tissue for pre-clinical drug testing.

Biotechnology · Enschede$2.0M Seed
Artica Therapeutics
November 2023

Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.

Biotechnology · Leiden$12.7M Seed
Dunad Therapeutics
November 2021

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Biotechnology · London$24.0M Series A
Panome Bio
November 2024

Panome Bio is a biomarker discovery platform offering biomarker analysis.

Bioinformatics · St Louis$6.0M Undisclosed
Rhygaze
January 2025

Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.

Biotechnology · Basel$86.0M Series A
Confo Therapeutics
October 2025

Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need.

Biotechnology · Brussels$1.2M Grant
Kivu Bioscience
October 2024

Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.

Biotechnology · San Francisco$92.0M Series A
Tessellate BIO
October 2023

Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.

Biotechnology · Naarden$8.5M Seed

Where BioGeneration Ventures invests

Biotechnology18
Health Care13
Medical10
Therapeutics9
Life Science4
Neuroscience3

About BioGeneration Ventures's portfolio

How many companies has BioGeneration Ventures invested in?

BioGeneration Ventures has invested in 47 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does BioGeneration Ventures invest in?

BioGeneration Ventures's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 18 different industry categories.

What is BioGeneration Ventures's largest investment?

Among tracked funding rounds, CatalYm received $150.0M in a Series D round. BioGeneration Ventures's total known invested capital is $2.2B.

What is the average investment size for BioGeneration Ventures?

BioGeneration Ventures's average investment size is $58.5M across its portfolio of 47 companies.

What are BioGeneration Ventures's most recent investments?

Recent BioGeneration Ventures portfolio additions include Tanai Therapeutics, Brenig Therapeutics, CatalYm, Dualyx, Phosphoenix. These companies were founded in 2020 or later.

Reach the founders behind these 47 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →